establishing safety and care requirements for clinician-administered drugs.
Subcommittee Work Session: 09/09/2026 10:00 am GP 229
Summary
The bill defines clinician‑administered drugs and bars health insurers or pharmacy benefit managers from requiring ‘white‑bagging’ or ‘brown‑bagging’ unless written agreements and consent are obtained. It also stops them from limiting coverage, raising costs, or penalizing providers who use non‑network pharmacies. The aim is to keep drug administration safe and preserve patient and provider choice.
AI-generated summary — may be incomplete or inaccurate. Verify against the official bill text.
Topics
Track this bill
Get real-time alerts when SB 256 changes status, plus AI-powered summaries and stage predictions.
Sign up free